Central Puerto ADR's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Central Puerto ADR reported revenue of $1.1T (+48.7% year on year) and net income of $352.8B (+476.0% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Revenue | $1.1T | $738.2B | $313.6B | $101.4B |
| Cost of sales | ($704.5B) | ($446.5B) | ($210.2B) | ($53.3B) |
| Gross income | $392.9B | $291.6B | $103.4B | $48.1B |
| Administrative and selling expenses | ($101.4B) | ($76.8B) | ($31.8B) | ($7.5B) |
| Non-Operating Income (Expense) | $129.7B | $125.7B | $237.7B | $35.9B |
| Other operating expenses | ($111.8B) | ($41.2B) | ($15.1B) | ($602.2M) |
| Impairment Reversal (Impairment) of property, plant and equipment and intangible assets | $61.0B | ($102.1B) | — | — |
| Operating income | $370.4B | $197.2B | $338.2B | $61.9B |
| Gain (Loss) on net monetary position | $6.4B | ($18.8B) | ($126.5B) | ($30.5B) |
| Interest Income | $125.5B | $117.3B | $230.2B | $25.5B |
| Finance expenses | ($243.6B) | ($171.6B) | ($356.8B) | ($43.5B) |
| Income from Equity Method Investments | $59.7B | $16.1B | $6.1B | $111.5M |
| Result from investments in entities measured at fair value | $134.6B | — | — | — |
| Income before income tax | $453.0B | $142.7B | $163.9B | $25.8B |
| Income tax for the year | ($100.2B) | ($81.5B) | ($17.9B) | ($6.7B) |
| Net income for the year | $352.8B | $61.3B | $146.0B | $19.1B |
| Net Income | $346.4B | $49.6B | $148.0B | $19.0B |
| Net Income Attributable to Noncontrolling Interest | $6.5B | $11.7B | ($2.1B) | $37.5M |
| Total net income loss for the year | $352.8B | — | — | — |
| Earnings Per Share (Basic) | $230.61 | $33.01 | — | — |
| Earnings Per Share (Diluted) | $230.61 | $33.01 | — | — |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Property, Plant and Equipment | $2.3T | $1.6T | $758.9B | $197.9B |
| Intangible assets | $40.5B | $30.7B | $16.0B | $7.8B |
| Biological assets | $191.6B | $186.8B | $89.2B | $12.3B |
| Investments in associates | $28.6B | $109.3B | $34.4B | $12.2B |
| Inventories | $12.6B | $4.3B | $6.0B | $2.2B |
| Other non-financial assets | $11.5B | $687.2M | $304.3M | $245.9M |
| Trade and other receivables | $128.2B | $136.7B | $154.6B | $42.3B |
| Other Non-Operating Non-Current Assets | $184.6B | $15.0B | $38.7B | $1.2B |
| Deferred Tax Assets, Non-Current | $4.2B | $6.4B | $12.7B | $835.7M |
| Total non current assets | $2.9T | $2.1T | $1.1T | $276.9B |
| Biological assets | $13.3B | $35.2B | $6.8B | $2.9B |
| Inventories | $28.3B | $21.8B | $8.9B | $6.3B |
| Other non-financial assets | $22.5B | $35.6B | $12.2B | $891.9M |
| Trade and other receivables | $320.4B | $217.7B | $161.3B | $43.9B |
| Other financial assets | $300.2B | $240.2B | $89.8B | $41.7B |
| Cash and Cash Equivalents | $37.7B | $3.8B | $13.5B | $9.2B |
| Total current assets | $722.4B | $554.3B | $292.5B | $105.0B |
| Total assets | $3.7T | $2.7T | $1.4T | $381.9B |
| Total Stockholders' Equity | $1.5B | $1.5B | $1.5B | $1.5B |
| Adjustment to capital stock | $559.6B | $539.5B | $246.9B | $78.3B |
| Treasury shares | 13.9M | — | — | — |
| Adjustment to treasury shares | 4.2B | — | — | — |
| Cost of treasury shares | -8.5B | — | — | — |
| Legal reserve | $142.3B | $106.0B | $41.3B | $12.3B |
| Accumulated Other Comprehensive Income | $992.0B | $754.1B | $346.3B | $156.0B |
| Other equity accounts | ($48.0B) | ($40.9B) | ($22.5B) | ($5.8B) |
| Voluntary reserve for future dividends distribution | $575.6B | $388.9B | $73.3B | — |
| Retained Earnings | $332.5B | $50.9B | $148.0B | $18.9B |
| Equity attributable to holders of the parent | $2.6T | $1.8T | $834.8B | $261.2B |
| Noncontrolling Interest | $64.8B | $63.1B | $21.8B | $198.0M |
| Total equity | $2.6T | $1.9T | $856.6B | $261.4B |
| Other non-financial liabilities | $21.7B | $24.8B | $28.1B | $7.6B |
| Loans and borrowings | $348.9B | $230.0B | $286.4B | $45.2B |
| Compensation and employee benefits liabilities | $9.7B | $7.7B | $3.3B | $745.5M |
| Warranty and Other Provisions | $9.5B | $2.2B | $1.9B | $59.4M |
| Income tax payable – Payment plan | $8.9B | — | — | — |
| Deferred Tax Liabilities, Non-Current | $247.4B | $158.8B | $79.2B | $24.5B |
| Total non current liabilities | $646.2B | $424.2B | $398.9B | $78.1B |
| Trade and other payables | $124.2B | $674.9M | $49.8B | $7.5B |
| Other non-financial liabilities | $55.9B | $30.6B | $25.6B | $8.8B |
| Loans and borrowings | $144.1B | $150.8B | $48.8B | $18.2B |
| Compensation and employee benefits liabilities | $43.6B | $33.9B | — | — |
| Taxes Payable | $35.8B | $60.7B | $6.3B | $4.8B |
| Provisions | $3.9B | $2.9B | $1.6B | $46.1M |
| Total current liabilities | $407.5B | $374.7B | $147.9B | $42.5B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Income for the year before income tax: | $453.0B | $142.7B | $163.9B | $25.8B |
| Depreciation of property, plant and equipment | $160.7B | $111.1B | $64.1B | $15.5B |
| Amortization of intangible assets | $2.3B | $2.7B | $6.1B | $4.0B |
| (Impairment Reversal) Impairment of property, plant and equipment and intangible assets | ($61.0B) | $102.1B | — | — |
| Loss on disposal of property, plant and equipment | $16.0B | — | — | — |
| (Charge) recovery for discount of tax credits | ($471.6M) | $96.5M | — | — |
| Interest earned from customers | ($24.0B) | ($32.0B) | ($33.4B) | ($6.7B) |
| Finance income | ($125.5B) | ($117.3B) | ($230.2B) | ($25.5B) |
| Finance expenses | $243.6B | $171.6B | $356.8B | $43.5B |
| Insurance recovery | ($18.9B) | ($9.6B) | $0 | ($1.3B) |
| Share of the profit of associates | ($59.7B) | ($16.1B) | ($6.1B) | ($111.5M) |
| Result from investment in entities mesuared at fair value | ($134.6B) | ($2.5B) | — | — |
| Material and spare parts impairment | $930.6M | $1.3B | $716.2M | $512.2M |
| Movements in provisions and long-term employee benefit plan expense | $6.0B | $12.0B | $3.7B | $343.9M |
| Biological assets revaluation | $87.0B | ($21.7B) | ($12.7B) | — |
| Foreign exchange difference for trade receivables | ($73.1B) | ($58.4B) | ($190.7B) | ($27.3B) |
| Results on net monetary position | ($60.3B) | ($41.9B) | — | — |
| Decrease in trade and other receivables | $15.5B | $61.4B | $43.0B | $10.0B |
| Decrease (Increase) in other non-financial assets, inventories and biological assets | $541.9M | $839.5M | ($32.3B) | $3.4B |
| Decrease in trade and other payables, other non-financial liabilities and liabilities from employee benefits | ($21.8B) | ($89.0B) | ($19.1B) | ($3.7B) |
| Interest received from customers | $21.5B | $36.8B | $29.3B | $5.8B |
| Income tax paid | ($21.3B) | ($14.9B) | ($34.3B) | ($8.0B) |
| Tax interest paid | ($957.7M) | ($805.2M) | — | — |
| Insurance recovery collected | $5.7B | $6.6B | $118.0M | $1.3B |
| Net cash flows provided by operating activities | $411.2B | $258.2B | $125.6B | $55.6B |
| Purchase of property, plant and equipment and materials | ($295.4B) | ($142.5B) | ($9.8B) | ($3.4B) |
| Dividends collected | $26.8B | $8.1B | $6.7B | $281.1M |
| Acquisition of associates | ($7.7B) | ($31.7B) | — | — |
| Acquisition of other financial assets, net | ($133.3M) | — | — | — |
| Net cash flows used in investing activities | ($276.4B) | ($164.9B) | ($63.6B) | ($31.3B) |
| Bank and investment accounts overdrafts received | $18.3B | $21.7B | — | — |
| Bank and investment accounts overdrafts paid | ($28.6B) | ($3.8B) | — | — |
| Loans and other financial debts received | $183.8B | $64.6B | $71.9B | $0 |
| Loans and other financial debts paid | ($233.2B) | ($130.9B) | ($93.1B) | ($8.5B) |
| Direct financing and loans refinancing costs paid | ($33.5B) | — | — | — |
| Bank fees and expenses paid | ($2.0B) | ($1.1B) | — | — |
| Dividends paid | ($1.0B) | ($16.7B) | ($21.9B) | ($3.6B) |
| Net cash flows used in financing activities | ($96.2B) | ($109.8B) | ($79.8B) | ($16.3B) |
| Increase (Decrease) in cash and cash equivalents | $38.5B | ($16.5B) | ($17.7B) | $8.1B |
| Exchange difference and other financial results | ($112.7M) | $1.0B | $20.4B | — |
| RECPAM generated by cash and cash equivalents | ($5.8B) | ($10.0B) | — | — |
| Cash and cash equivalents as of January 1 | $5.1B | $29.3B | $28.8B | — |
| Cash and cash equivalents as of December 31 | $37.7B | $3.8B | $13.5B | — |
| Acquisition of PP&E pending payment and through pre-financing | $19.2B | $47.1B | — | — |
| Acquisition of financial assets through the TRUST | $32.8B | $20.8B | — | — |
Central Puerto ADR score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.